Insulin Autoimmune Syndrome (Hirata Disease) and Its Supplement and Drug Triggers

Insulin autoimmune syndrome (IAS), also called Hirata disease, is a rare cause of low blood sugar in people who have never injected insulin. The immune system makes large amounts of antibodies against the body's own insulin. Those antibodies hold on to insulin after a meal and let it go later, when it is no longer needed, and blood sugar falls. The records describe the condition as usually set off by a trigger acting on an inherited tissue type: most often a medicine or a supplement that carries a sulfur-and-hydrogen group (a sulfhydryl, or thiol, group), with a growing number of cases attributed to the supplement alpha-lipoic acid (Vallianou 2026).

This page covers what the syndrome is, how it differs from an insulin-making tumor and from antibodies to injected insulin, the drugs and supplements named in the case records, the European Food Safety Authority's review of 49 alpha-lipoic acid cases, the tissue types linked to it, how it is diagnosed, how cases ended once the trigger was stopped, and what is still not known. The alpha-lipoic acid evidence for blood sugar itself is on Alpha Lipoic Acid for Blood Sugar & Insulin Sensitivity, and the general levels and symptoms of low blood sugar are on Hypoglycemia Awareness and Prevention.

Table of Contents

  1. An Immune Reaction to the Body's Own Insulin
  2. How It Differs From a Tumor and From Injected-Insulin Antibodies
  3. Sulfhydryl Drugs Are the Triggers Named Most Often
  4. Alpha-Lipoic Acid and the European Review of 49 Cases
  5. Inherited Tissue Types Shape Who Is Affected
  6. Diagnosis Rests on Finding Insulin Antibodies
  7. Most Recorded Cases Ended After the Trigger Was Stopped
  8. Low Blood Sugar Signs in These Cases Are Treated as Urgent
  9. Large Gaps Remain in What Is Known
  10. Key Research Papers
  11. Connections
  12. Featured Videos

An Immune Reaction to the Body's Own Insulin

The syndrome was first reported by Hirata and colleagues in 1970. A 1994 review of the Japanese records counted 197 cases reported in Japan by December 1992 (Uchigata 1994). In those 197 cases the most common age at onset was 60 to 69 years, the hypoglycemic attacks most often lasted more than 1 and less than 3 months, and there was no difference between men and women in age of onset or in how long the attacks lasted.

A 2020 review written fifty years after the first description sets out the mechanism as a two-phase process (Cappellani 2020). The antibodies bind insulin and form insulin-antibody complexes. After a meal, the antibodies keep insulin from reaching its receptor, which can produce mildly high blood sugar. Later, insulin is released from the complexes regardless of the blood glucose level, and that free insulin drives blood sugar down. The same review describes the syndrome as developing when a triggering factor, such as a medication or a viral infection, acts on an underlying genetic background.

A 2026 review describes the antibodies as high-capacity and low-affinity: they bind insulin after meals and release it unpredictably, producing high blood sugar after eating followed by delayed low blood sugar (Nahar 2026). A 2023 systematic review describes the condition as recurrent episodes of severe hypoglycemia with markedly raised blood insulin and positive insulin antibodies (Lin 2023). In the six European patients described in 2014, the low blood sugar came both during fasting and after the meal had been absorbed, with mainly neuroglycopenic symptoms, the brain-starvation symptoms such as confusion (Gullo 2014).

Japanese researchers also separated two kinds of antibody response. Most cases are polyclonal, meaning many different antibody-making cell lines are involved; a smaller group is monoclonal, coming from a single cell line, and the two forms were tied to different inherited tissue types (Uchigata 1995).

Back to Table of Contents

How It Differs From a Tumor and From Injected-Insulin Antibodies

Three conditions can all produce low blood sugar with high insulin levels, and the records separate them carefully.

Insulinoma. An insulinoma is a tumor of the insulin-making beta cells that releases insulin on its own. A 2018 review lists the features that define insulin autoimmune syndrome as low blood sugar with high insulin, raised insulin antibody levels, no prior exposure to injected insulin, and no disease of the pancreatic islets (Censi 2018). Overlap does happen. A 2024 Japanese case report describes an 89-year-old woman with a 14 mm tumor in the tail of the pancreas whose blood also carried anti-insulin antibodies (21.1 U/mL), although she had never injected insulin or taken alpha-lipoic acid or sulfhydryl-containing agents (Nakajima 2024). Her insulin-to-C-peptide molar ratio was 0.14, and the authors list that ratio and the serum insulin level as useful for telling an insulinoma apart from the autoimmune syndrome.

Antibodies to injected insulin. People who inject insulin can also form insulin antibodies. A 2020 review names that condition exogenous insulin antibody syndrome and contrasts it with insulin autoimmune syndrome, which occurs in people who have never received insulin (Huynh 2020). A case report and review describes the injected-insulin form as a rare hypersensitivity reaction that can bring insulin resistance, high blood sugar, recurrent low blood sugar and allergic reactions (Gao 2025). In two Japanese men with type 1 diabetes, recurrent low blood sugar from a high insulin antibody level subsided after the insulin regimen or preparation was changed; the antibody measurements were essentially the same as in insulin autoimmune syndrome, the difference being that these men had been given insulin (Kawamura 2022).

Insulin receptor antibodies. A second autoimmune form of low blood sugar, type B insulin resistance syndrome, is caused by antibodies against the insulin receptor rather than against insulin itself, and it can range from low blood sugar to extremely insulin-resistant high blood sugar (Censi 2018).

Back to Table of Contents

Sulfhydryl Drugs Are the Triggers Named Most Often

In the Japanese records up to 1992, 43% of the patients had been taking medication before diagnosis: methimazole for Graves' disease, alpha-mercaptopropionyl glycine for cataracts, liver disease or rheumatoid arthritis, or glutathione for liver disease, all of them sulfhydryl compounds (Uchigata 1994). After these compounds were stopped, the hypoglycemic attacks subsided. A 2026 review calls methimazole the classical drug-associated cause and describes an increasing number of cases attributed to alpha-lipoic acid (Vallianou 2026). Reviews also name viral infections, and less commonly autoimmune and blood disorders, among the settings in which the syndrome has appeared (Cappellani 2020; Vallianou 2026).

Methimazole. A 2016 case report describes a 76-year-old woman with hyperthyroidism, taking methimazole and no insulin or sulfonylurea, who arrived unresponsive with low blood pressure and low blood sugar (Jain 2016). Her low blood sugar kept returning for days despite dextrose infusions, octreotide and glucagon; after day 11 the episodes resolved and her blood sugar stayed normal on its own. Methimazole is a drug used for Graves' disease, and in a 2024 analysis of genetically tested cases it was the primary drug associated with the syndrome in people of East Asian descent (Yao 2024).

Clopidogrel. The antiplatelet drug clopidogrel produces a metabolite that carries a sulfhydryl group. A 2023 systematic case review assembled 51 patients with clopidogrel-induced insulin autoimmune syndrome and compared them with 287 cases from other causes (Chen 2023). The clopidogrel group had an average onset age of 74.8±8.6 years, was 92.2% male, and was balanced between East Asian and non-East Asian patients. Confusion occurred more often than in cases from other causes. The authors found that ticagrelor and rivaroxaban were unlikely to induce low blood sugar or the syndrome, and wrote that substituting them for clopidogrel might be considered.

The wider drug list. A 2025 study combined 228 cases from the United States Food and Drug Administration's adverse event reporting system (2004 to the second quarter of 2024) with a systematic review of 263 published cases from 1980 to 2024 (Yu 2025). It found 58 agents with possible links to the syndrome, including 12 new signals such as bevacizumab, sitagliptin, amlodipine and olmesartan. Thiol-containing drugs had the strongest signals (proportional reporting ratio above 200), for example captopril, methimazole and clopidogrel. The highest level of evidence implicated clopidogrel, captopril, omeprazole and methimazole. The patients had a median age of 66 years, 59.21% were male, and 85.17% of the published cases came from Asia. Reports of low blood sugar exceeded reports of the syndrome for most agents, which the authors read as a sign of underdiagnosis.

Back to Table of Contents

Alpha-Lipoic Acid and the European Review of 49 Cases

Alpha-lipoic acid is a sulfur-containing compound that is widely used as a nutritional supplement and sometimes as an add-on treatment for diabetic nerve damage (Gullo 2014). The alpha-lipoic acid page covers the compound itself; this section covers the insulin autoimmune syndrome records in more depth.

What the European Food Safety Authority was asked. At the request of the European Commission, the European Food Safety Authority's panel on nutrition, novel foods and food allergens delivered a 2021 opinion on the relationship between alpha-lipoic acid and the risk of insulin autoimmune syndrome, and was asked to advise on a dose below which alpha-lipoic acid added to foods would not be expected to cause it (European Food Safety Authority 2021). A review of every possible adverse effect of alpha-lipoic acid was not part of the request. The panel noted that no pre-established rule exists for judging the safety of foods when classical toxicity tests cannot be used, as with autoimmune diseases.

What the panel found. Its literature searches retrieved 49 case reports in which the syndrome developed after alpha-lipoic acid was taken. In all of them, the syndrome resolved after a few weeks to months once alpha-lipoic acid was discontinued. No publication linked alpha-lipoic acid occurring naturally in foods to the syndrome.

What the panel concluded. Taking alpha-lipoic acid added to foods, including food supplements, is likely to increase the risk of insulin autoimmune syndrome in people with certain genetic variants, who cannot readily be identified without genetic testing. The way this happens has not been fully worked out. The syndrome is uncommon in Europe and likely less common than in Japan, where incidence was estimated at 0.017 per 100,000 inhabitants in 2017-2018. Because data are limited, the risk could not be quantified precisely, and a dose below which the syndrome is not expected is likely to vary between individuals and could not be determined.

The European patients. Before 2014 only one case had been reported in white people. That year, a report from Italy described six (three men and three women, median age 63) taking alpha-lipoic acid at 600 mg/day, none treated with insulin and none with an insulinoma (Gullo 2014). Their symptoms appeared 30 and 120 days after starting it. Stopping alpha-lipoic acid reduced the hypoglycemic episodes. The authors expected more cases, given how common the tissue type they found is in white and other populations and how widely alpha-lipoic acid is used in developed countries. A 2024 analysis of genetically tested patients found lipoic acid to be the common inducer in white patients (Yao 2024).

Beyond Europe and Japan. A 2023 case report from India describes a previously healthy man with recurrent low blood sugar who had never received insulin and was taking alpha-lipoic acid (Sehgal 2023). His insulin was above 1000 µIU/mL, his C-peptide 12.8 ng/ml, and his insulin antibody titer above 100 units/mL against a normal range below 10 units/mL. A 2026 Greek review presents a 76-year-old man who developed the syndrome after alpha-lipoic acid supplementation (Vallianou 2026).

Back to Table of Contents

Inherited Tissue Types Shape Who Is Affected

Human leukocyte antigen (HLA) genes set the "tissue type" that decides which protein fragments the immune system is shown. Older papers write the alleles without a colon (DRB1*0406), newer ones with it (DRB1*04:06); the figures below keep each record's own notation.

The Japanese findings. Japanese patients with the polyclonal form showed a striking association with the class II alleles DRB1*0406/DQA1*0301/DQB1*0302, and their T cells recognized human insulin in the context of DRB1*0406 molecules (Uchigata 1995). The researchers presumed that glutamate at position 74 of the HLA-DR4 beta chain was essential to the polyclonal antibody response, while alanine at the same position might matter for the monoclonal form. A 2000 study reported that DRB1*0406 is associated with increased susceptibility among Japanese people, while DRB1*0403 and DRB1*0407 are not (odds ratios 1.6 and 1.1) (Uchigata 2000). The authors explained the extremely low prevalence of the syndrome among white people by the low prevalence of DRB1*0406 in that population.

The European findings. In the six European alpha-lipoic acid patients, five carried HLA-DRB1*04:03 and one HLA-DRB1*04:06 (Gullo 2014). The authors called this the first report of lipoic acid-related cases in white people carrying HLA-DRB1*04:03, implicating that allele in their susceptibility.

The 68-case review. A 2024 analysis noted that hundreds of cases had been reported worldwide but fewer than a hundred patients had undergone genetic testing (Yao 2024). Its HLA analysis of 68 cases found DR4 predominant, especially in people of East Asian descent, notably DRB1 *0406, where methimazole was the main associated drug. In white patients the emphasis was on DRB1 *0403, with lipoic acid the common inducer. The authors concluded that the key factor is the combination of allele variations, with HLA class II DR4-positive patients showing a strong association with DQA1 *0301/DQB1 *0302. A 2026 review lists HLA-DRB1*04:06, 04:03 and 04:04 as the susceptibility alleles in which sulfhydryl compounds are thought to alter how the immune system sees insulin (Vallianou 2026), and another names HLA-DR4-related alleles, particularly DRB1*0406, as raising susceptibility (Nahar 2026).

Back to Table of Contents

Diagnosis Rests on Finding Insulin Antibodies

The 2020 review calls the diagnosis challenging: it needs a careful workup that rules out other causes of low blood sugar with high insulin, and the gold standard for a definitive diagnosis is finding insulin autoantibodies in a blood sample (Cappellani 2020). The 2023 systematic review adds that C-peptide, the fragment released when the body makes its own insulin, does not rise in step with insulin, which could be diagnostic (Lin 2023). The C-peptide test page explains that marker.

Laboratory traps are a recurring theme. A 2016 review notes that the antibodies can interfere with the immunoassay tests used to measure pancreatic hormones, producing erroneous and potentially misleading results, and describes thorough testing for insulin antibodies as a step in investigating unexplained low blood sugar in people without diabetes who are not acutely ill (Ismail 2016). The 2026 review lists immunoassay interference, insulin levels out of proportion to everything else, and pancreatic imaging that shows no insulinoma as the usual diagnostic challenges (Nahar 2026). The Indian case report highlights insulin antibody titers as a first-line test for low blood sugar in a person without diabetes whose insulin is strikingly high (Sehgal 2023).

A 2018 review notes that among white people autoimmune low blood sugar is often misdiagnosed, which exposes patients to long series of pointless, potentially harmful and expensive tests (Censi 2018). A 2020 laboratory review points out that experts still disagree on the name, definition and diagnostic criteria, and that diagnosis is often delayed (Huynh 2020).

Back to Table of Contents

Most Recorded Cases Ended After the Trigger Was Stopped

The Japanese series. About 82% of the 197 Japanese patients had a spontaneous remission without any active treatment (Uchigata 1994). When the sulfhydryl compounds were stopped, the attacks subsided. Three patients had the attacks return after methimazole or alpha-mercaptopropionyl glycine was given again. Six patients who had developed the syndrome without any drug exposure had recurrent attacks about a year after the first attacks had stopped, again without any drug. The authors concluded that the low blood sugar is mainly transient.

The alpha-lipoic acid cases. In all 49 case reports reviewed by the European Food Safety Authority, the syndrome resolved after a few weeks to months once alpha-lipoic acid was discontinued (European Food Safety Authority 2021). In the six European patients, stopping it reduced the hypoglycemic episodes; all six were treated with glucose by mouth or vein and with prednisone at 12.5-25 mg/day (Gullo 2014).

The clopidogrel cases. Recovery time was about the same whether or not the patients received glucocorticoids or other immune treatment, and the authors wrote that such treatment might not be necessary for long-term recovery (Chen 2023).

Treatments described in the reviews. Because the syndrome often goes away on its own, the 2020 review describes management mostly as supportive, such as changes in diet to prevent low blood sugar; for severe cases the reported options include drugs that reduce insulin release from the pancreas (somatostatin analogues and diazoxide) and immunosuppressants (glucocorticoids, azathioprine and rituximab) (Cappellani 2020). The 2023 systematic review adds acarbose, a drug that slows the absorption of glucose, and plasma exchange to remove the antibodies, and describes the syndrome as self-limiting with a good prognosis (Lin 2023). The 2026 alpha-lipoic acid review points to medical nutrition therapy with frequent, small meals rich in cornstarch, together with acarbose or glucocorticoids, and links withdrawal of the trigger, together with supportive and drug management, to a favorable outcome in most patients (Vallianou 2026). The 2016 laboratory review records that extreme cases have needed plasmapheresis for blood sugar control (Ismail 2016).

Back to Table of Contents

Low Blood Sugar Signs in These Cases Are Treated as Urgent

The records do not describe a mild nuisance. The 2020 laboratory review states that the low blood sugar is often life-threatening (Huynh 2020). The methimazole patient arrived unresponsive and needed intensive care (Jain 2016). In the clopidogrel series, confusion occurred more often than in cases from other causes (Chen 2023), and the European alpha-lipoic acid patients had mainly neuroglycopenic symptoms (Gullo 2014). The 2016 laboratory review describes a range from mild and transient to spontaneous, severe and long-lasting low blood sugar (Ismail 2016).

Confusion, unusual behavior, slurred speech, unresponsiveness and seizures from low blood sugar are signs hospitals treat as urgent. Because the attacks in this syndrome can come after a meal or during fasting, and in a person who does not have diabetes, the low may not be recognized for what it is. The levels and the full list of early and late symptoms are set out on Hypoglycemia Awareness and Prevention.

Back to Table of Contents

Large Gaps Remain in What Is Known

Back to Table of Contents

Key Research Papers

  1. Uchigata Y, Eguchi Y, Takayama-Hasumi S, Omori Y. Insulin autoimmune syndrome (Hirata disease): clinical features and epidemiology in Japan. Diabetes Res Clin Pract. 1994;22(2-3):89-94. PubMed PMID: 8200300
  2. Uchigata Y, Tokunaga K, Nepom G, Bannai M, Kuwata S, Dozio N, et al. Differential immunogenetic determinants of polyclonal insulin autoimmune syndrome (Hirata's disease) and monoclonal insulin autoimmune syndrome. Diabetes. 1995;44(10):1227-32. PubMed PMID: 7556962
  3. Uchigata Y, Hirata Y, Omori Y, Iwamoto Y, Tokunaga K. Worldwide differences in the incidence of insulin autoimmune syndrome (Hirata disease) with respect to the evolution of HLA-DR4 alleles. Hum Immunol. 2000;61(2):154-7. PubMed PMID: 10717808
  4. Gullo D, Evans JL, Sortino G, Goldfine ID, Vigneri R. Insulin autoimmune syndrome (Hirata Disease) in European Caucasians taking α-lipoic acid. Clin Endocrinol (Oxf). 2014;81(2):204-9. PubMed PMID: 24111525
  5. Jain N, Savani M, Agarwal M, Kadaria D. Methimazole-induced insulin autoimmune syndrome. Ther Adv Endocrinol Metab. 2016;7(4):178-81. PubMed PMID: 27540463
  6. Ismail AA. The insulin autoimmune syndrome (IAS) as a cause of hypoglycaemia: an update on the pathophysiology, biochemical investigations and diagnosis. Clin Chem Lab Med. 2016;54(11):1715-1724. PubMed PMID: 27071154
  7. Censi S, Mian C, Betterle C. Insulin autoimmune syndrome: from diagnosis to clinical management. Ann Transl Med. 2018;6(17):335. PubMed PMID: 30306074
  8. Cappellani D, Macchia E, Falorni A, Marchetti P. Insulin Autoimmune Syndrome (Hirata Disease): A Comprehensive Review Fifty Years After Its First Description. Diabetes Metab Syndr Obes. 2020;13:963-978. PubMed PMID: 32308449
  9. Huynh T. Clinical and Laboratory Aspects of Insulin Autoantibody-Mediated Glycaemic Dysregulation and Hyperinsulinaemic Hypoglycaemia: Insulin Autoimmune Syndrome and Exogenous Insulin Antibody Syndrome. Clin Biochem Rev. 2020;41(3):93-102. PubMed PMID: 33343044
  10. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Castenmiller J, de Henauw S, Hirsch-Ernst KI, Kearney J, et al. Scientific opinion on the relationship between intake of alpha-lipoic acid (thioctic acid) and the risk of insulin autoimmune syndrome. EFSA J. 2021;19(6):e06577. PubMed PMID: 34122657
  11. Kawamura R, Miyao S, Onuma H, Uchigata Y, Kawasaki E, Ohashi J, et al. Recurrent Hypoglycemia Due to a High Titer of Insulin Antibody in Response to Exogenous Insulin Administration in Two Cases of Type 1 Diabetes. Intern Med. 2022;61(5):687-695. PubMed PMID: 34471020
  12. Lin M, Chen Y, Ning J. Insulin Autoimmune Syndrome: A Systematic Review. Int J Endocrinol. 2023;2023:1225676. PubMed PMID: 36844104
  13. Sehgal T, Ohri U, Mittal N, Attri P, Dishant F. A Case of Insulin Autoimmune Syndrome in an Indian Male Taking Alpha-Lipoic Acid. Cureus. 2023;15(8):e43743. PubMed PMID: 37727171
  14. Chen S, Qiang J, Zhao B, Tian R, Yuan T, Li M, et al. Clopidogrel as a Distinctive Cause of Insulin Autoimmune Syndrome: A Systematic Case Review. Diabetes Metab Syndr Obes. 2023;16:2583-2592. PubMed PMID: 37649588
  15. Nakajima R, Sato D, Togashi I, Idesawa H, Ito J, Ito K, et al. Insulinoma presenting with anti-insulin antibodies. Endocrinol Diabetes Metab Case Rep. 2024;2024(3):24-0062. PubMed PMID: 39133227
  16. Yao D, Jiang J, Zhou Q, Feng C, Chu J, Chen Z, et al. HLA Alleles Associate with Insulin Autoimmune Syndrome. Diabetes Metab Syndr Obes. 2024;17:3463-3475. PubMed PMID: 39309309
  17. Yu X, Li M, Liao Y, Xie Y, Xu J, Long Y, et al. Drug-induced insulin autoimmune syndrome: a clinico-epidemiological analysis integrating pharmacovigilance data and case series. Diabetol Metab Syndr. 2025;17(1):387. PubMed PMID: 41068837
  18. Gao Y, Wang N, Huang Z, Bai N. Exogenous insulin autoimmune syndrome: a case report and literature review. Front Endocrinol (Lausanne). 2025;16:1700742. PubMed PMID: 41585798
  19. Nahar S, Nahida N, Setu HJ, Aishi AS, Das U, Rosy D, et al. Insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management. Dis Mon. 2026;72(10):102146. PubMed PMID: 42143009
  20. Vallianou NG, Kounatidis DC, Dalamaga M, Panagopoulos F, Psaroudaki M, Tantsi I, et al. Alpha-lipoic acid as a trigger of insulin autoimmune syndrome: Current evidence, a case-based approach, diagnostic pitfalls, and practical management. Metabol Open. 2026;31:100491. PubMed PMID: 42662728

PubMed Topic Searches

  1. PubMed: insulin autoimmune syndrome and alpha-lipoic acid
  2. PubMed: insulin autoimmune syndrome and HLA tissue types
  3. PubMed: insulin autoimmune syndrome and methimazole
  4. PubMed: insulin autoimmune syndrome and clopidogrel
  5. PubMed: Hirata disease reviews

Back to Table of Contents

Connections

Back to Table of Contents